Therapeutic effects of hyaluronidase on acquired lymphedema using a newly developed mouse limb model.
Identifieur interne : 000415 ( PubMed/Corpus ); précédent : 000414; suivant : 000416Therapeutic effects of hyaluronidase on acquired lymphedema using a newly developed mouse limb model.
Auteurs : Kangsan Roh ; Sungrae Cho ; Jae-Hyun Park ; Byong Chul Yoo ; Won-Ki Kim ; Seok-Ki Kim ; Kyewon Park ; Hee Kang ; Jin-Mo Ku ; Chang-Hwan Yeom ; Kyunghoon Lee ; Sukchan LeeSource :
- Experimental biology and medicine (Maywood, N.J.) [ 1535-3699 ] ; 2017.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Hyaluronoglucosaminidase.
- complications : Neoplasms.
- drug therapy : Lymphedema.
- etiology : Lymphedema.
- Animals, Disease Models, Animal, Hindlimb, Lymph Node Excision, Male, Mice, Mice, Inbred ICR.
Abstract
Acquired lymphedema is one of the most dreaded side effects of cancer treatment, such as surgical treatment or irradiation. However, due to the lack of appropriate animal models, there is no effective therapeutic method to cure acquired lymphedema. To develop a reproducible acquired lymphedema animal model, we devised a mouse hind limb model by removing a superficial inguinal lymph node, a popliteal lymph node, a deep inguinal lymph node, and the femoral lymphatic vessel. We measured the volume of lymphedematous leg and observed the change in level of hyaluronic acid (HA) and lymphangiogenic factors after injecting hyaluronidase. Our model showed the distinguishable swelling and the reliable symptoms compared to previously reported models. In the lymphedematous regions of our model, we confirmed that HA, a major component of extracellular matrix, accumulated to higher levels than in a normal mouse. This lymphedema volume was rapidly reduced by treating hyaluronidase. Following hyaluronidase injection, the lymphedematous region of our model resembled a normal hind limb. Our findings indicated that hyaluronidase promoted lymphangiogenesis on the lymphedematous limb. Based on hyaluronidase treatment in the lymphedematous region, this could potentially be a new therapeutic approach for acquired lymphedema mediated through the modification of the size of HA fragments. Impact statement In this manuscript, the essence of the work described in this manuscript involves the development of (1) a mouse limb model showing acquired lymphedema and (2) a potent therapeutic treatment using hyaluronidase to remedy acquired lymphedema in our model. In order to develop a reproducible acquired lymphedema animal model that reflects the most common symptoms experienced by lymphedema patients, we devised a mouse hind limb model by removing lymph nodes and lymphatics. Our model showed the distinguishable swelling and the reliable symptoms compared to previously reported models. In the lymphedematous regions of our model, we confirmed that hyaluronic acid (HA) accumulated to higher levels than in a normal mouse. This lymphedema volume was rapidly reduced by treating the lymphedematous leg with hyaluronidase, which also degraded high molecular weight HA to low molecular weight HA. Immunohistochemical analysis, quantitative real-time PCR analysis and lymphangioscintigraphy showed that hyaluronidase enhanced lymphangiogenesis in the lymphedematous limb.
DOI: 10.1177/1535370216688570
PubMed: 28092183
Links to Exploration step
pubmed:28092183Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic effects of hyaluronidase on acquired lymphedema using a newly developed mouse limb model.</title><author><name sortKey="Roh, Kangsan" sort="Roh, Kangsan" uniqKey="Roh K" first="Kangsan" last="Roh">Kangsan Roh</name><affiliation><nlm:affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Cho, Sungrae" sort="Cho, Sungrae" uniqKey="Cho S" first="Sungrae" last="Cho">Sungrae Cho</name><affiliation><nlm:affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Park, Jae Hyun" sort="Park, Jae Hyun" uniqKey="Park J" first="Jae-Hyun" last="Park">Jae-Hyun Park</name><affiliation><nlm:affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Yoo, Byong Chul" sort="Yoo, Byong Chul" uniqKey="Yoo B" first="Byong Chul" last="Yoo">Byong Chul Yoo</name><affiliation><nlm:affiliation>2 Colorectal Cancer Branch, Division of Translational and Clinical Research I, Research Institute, National Cancer Center, Goyang 410-769, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Won Ki" sort="Kim, Won Ki" uniqKey="Kim W" first="Won-Ki" last="Kim">Won-Ki Kim</name><affiliation><nlm:affiliation>2 Colorectal Cancer Branch, Division of Translational and Clinical Research I, Research Institute, National Cancer Center, Goyang 410-769, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Seok Ki" sort="Kim, Seok Ki" uniqKey="Kim S" first="Seok-Ki" last="Kim">Seok-Ki Kim</name><affiliation><nlm:affiliation>3 Molecular Imaging & Therapy Branch, National Cancer Center, Goyang 410-769, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Park, Kyewon" sort="Park, Kyewon" uniqKey="Park K" first="Kyewon" last="Park">Kyewon Park</name><affiliation><nlm:affiliation>4 Department of Food Science and Biotechnology, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kang, Hee" sort="Kang, Hee" uniqKey="Kang H" first="Hee" last="Kang">Hee Kang</name><affiliation><nlm:affiliation>5 Department of Oriental Medical Science, Graduate School of East-West Medicine, Kyunghee University, Secheondong, Yongin 446-701, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Ku, Jin Mo" sort="Ku, Jin Mo" uniqKey="Ku J" first="Jin-Mo" last="Ku">Jin-Mo Ku</name><affiliation><nlm:affiliation>6 Natural Products Research Department, Gyeonggi Institute of Science & Technology, Suwon 443-270, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Yeom, Chang Hwan" sort="Yeom, Chang Hwan" uniqKey="Yeom C" first="Chang-Hwan" last="Yeom">Chang-Hwan Yeom</name><affiliation><nlm:affiliation>7 U-Cell Clinic, Seoul 137-071, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Kyunghoon" sort="Lee, Kyunghoon" uniqKey="Lee K" first="Kyunghoon" last="Lee">Kyunghoon Lee</name><affiliation><nlm:affiliation>8 Department of Anatomy, School of Medicine, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Sukchan" sort="Lee, Sukchan" uniqKey="Lee S" first="Sukchan" last="Lee">Sukchan Lee</name><affiliation><nlm:affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28092183</idno><idno type="pmid">28092183</idno><idno type="doi">10.1177/1535370216688570</idno><idno type="wicri:Area/PubMed/Corpus">000415</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000415</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic effects of hyaluronidase on acquired lymphedema using a newly developed mouse limb model.</title><author><name sortKey="Roh, Kangsan" sort="Roh, Kangsan" uniqKey="Roh K" first="Kangsan" last="Roh">Kangsan Roh</name><affiliation><nlm:affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Cho, Sungrae" sort="Cho, Sungrae" uniqKey="Cho S" first="Sungrae" last="Cho">Sungrae Cho</name><affiliation><nlm:affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Park, Jae Hyun" sort="Park, Jae Hyun" uniqKey="Park J" first="Jae-Hyun" last="Park">Jae-Hyun Park</name><affiliation><nlm:affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Yoo, Byong Chul" sort="Yoo, Byong Chul" uniqKey="Yoo B" first="Byong Chul" last="Yoo">Byong Chul Yoo</name><affiliation><nlm:affiliation>2 Colorectal Cancer Branch, Division of Translational and Clinical Research I, Research Institute, National Cancer Center, Goyang 410-769, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Won Ki" sort="Kim, Won Ki" uniqKey="Kim W" first="Won-Ki" last="Kim">Won-Ki Kim</name><affiliation><nlm:affiliation>2 Colorectal Cancer Branch, Division of Translational and Clinical Research I, Research Institute, National Cancer Center, Goyang 410-769, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Seok Ki" sort="Kim, Seok Ki" uniqKey="Kim S" first="Seok-Ki" last="Kim">Seok-Ki Kim</name><affiliation><nlm:affiliation>3 Molecular Imaging & Therapy Branch, National Cancer Center, Goyang 410-769, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Park, Kyewon" sort="Park, Kyewon" uniqKey="Park K" first="Kyewon" last="Park">Kyewon Park</name><affiliation><nlm:affiliation>4 Department of Food Science and Biotechnology, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kang, Hee" sort="Kang, Hee" uniqKey="Kang H" first="Hee" last="Kang">Hee Kang</name><affiliation><nlm:affiliation>5 Department of Oriental Medical Science, Graduate School of East-West Medicine, Kyunghee University, Secheondong, Yongin 446-701, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Ku, Jin Mo" sort="Ku, Jin Mo" uniqKey="Ku J" first="Jin-Mo" last="Ku">Jin-Mo Ku</name><affiliation><nlm:affiliation>6 Natural Products Research Department, Gyeonggi Institute of Science & Technology, Suwon 443-270, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Yeom, Chang Hwan" sort="Yeom, Chang Hwan" uniqKey="Yeom C" first="Chang-Hwan" last="Yeom">Chang-Hwan Yeom</name><affiliation><nlm:affiliation>7 U-Cell Clinic, Seoul 137-071, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Kyunghoon" sort="Lee, Kyunghoon" uniqKey="Lee K" first="Kyunghoon" last="Lee">Kyunghoon Lee</name><affiliation><nlm:affiliation>8 Department of Anatomy, School of Medicine, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Sukchan" sort="Lee, Sukchan" uniqKey="Lee S" first="Sukchan" last="Lee">Sukchan Lee</name><affiliation><nlm:affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Experimental biology and medicine (Maywood, N.J.)</title><idno type="eISSN">1535-3699</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Hindlimb</term><term>Hyaluronoglucosaminidase (therapeutic use)</term><term>Lymph Node Excision</term><term>Lymphedema (drug therapy)</term><term>Lymphedema (etiology)</term><term>Male</term><term>Mice</term><term>Mice, Inbred ICR</term><term>Neoplasms (complications)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hyaluronoglucosaminidase</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Hindlimb</term><term>Lymph Node Excision</term><term>Male</term><term>Mice</term><term>Mice, Inbred ICR</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Acquired lymphedema is one of the most dreaded side effects of cancer treatment, such as surgical treatment or irradiation. However, due to the lack of appropriate animal models, there is no effective therapeutic method to cure acquired lymphedema. To develop a reproducible acquired lymphedema animal model, we devised a mouse hind limb model by removing a superficial inguinal lymph node, a popliteal lymph node, a deep inguinal lymph node, and the femoral lymphatic vessel. We measured the volume of lymphedematous leg and observed the change in level of hyaluronic acid (HA) and lymphangiogenic factors after injecting hyaluronidase. Our model showed the distinguishable swelling and the reliable symptoms compared to previously reported models. In the lymphedematous regions of our model, we confirmed that HA, a major component of extracellular matrix, accumulated to higher levels than in a normal mouse. This lymphedema volume was rapidly reduced by treating hyaluronidase. Following hyaluronidase injection, the lymphedematous region of our model resembled a normal hind limb. Our findings indicated that hyaluronidase promoted lymphangiogenesis on the lymphedematous limb. Based on hyaluronidase treatment in the lymphedematous region, this could potentially be a new therapeutic approach for acquired lymphedema mediated through the modification of the size of HA fragments. Impact statement In this manuscript, the essence of the work described in this manuscript involves the development of (1) a mouse limb model showing acquired lymphedema and (2) a potent therapeutic treatment using hyaluronidase to remedy acquired lymphedema in our model. In order to develop a reproducible acquired lymphedema animal model that reflects the most common symptoms experienced by lymphedema patients, we devised a mouse hind limb model by removing lymph nodes and lymphatics. Our model showed the distinguishable swelling and the reliable symptoms compared to previously reported models. In the lymphedematous regions of our model, we confirmed that hyaluronic acid (HA) accumulated to higher levels than in a normal mouse. This lymphedema volume was rapidly reduced by treating the lymphedematous leg with hyaluronidase, which also degraded high molecular weight HA to low molecular weight HA. Immunohistochemical analysis, quantitative real-time PCR analysis and lymphangioscintigraphy showed that hyaluronidase enhanced lymphangiogenesis in the lymphedematous limb.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28092183</PMID><DateCreated><Year>2017</Year><Month>01</Month><Day>16</Day></DateCreated><DateCompleted><Year>2017</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-3699</ISSN><JournalIssue CitedMedium="Internet"><Volume>242</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Experimental biology and medicine (Maywood, N.J.)</Title><ISOAbbreviation>Exp. Biol. Med. (Maywood)</ISOAbbreviation></Journal><ArticleTitle>Therapeutic effects of hyaluronidase on acquired lymphedema using a newly developed mouse limb model.</ArticleTitle><Pagination><MedlinePgn>584-592</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1535370216688570</ELocationID><Abstract><AbstractText>Acquired lymphedema is one of the most dreaded side effects of cancer treatment, such as surgical treatment or irradiation. However, due to the lack of appropriate animal models, there is no effective therapeutic method to cure acquired lymphedema. To develop a reproducible acquired lymphedema animal model, we devised a mouse hind limb model by removing a superficial inguinal lymph node, a popliteal lymph node, a deep inguinal lymph node, and the femoral lymphatic vessel. We measured the volume of lymphedematous leg and observed the change in level of hyaluronic acid (HA) and lymphangiogenic factors after injecting hyaluronidase. Our model showed the distinguishable swelling and the reliable symptoms compared to previously reported models. In the lymphedematous regions of our model, we confirmed that HA, a major component of extracellular matrix, accumulated to higher levels than in a normal mouse. This lymphedema volume was rapidly reduced by treating hyaluronidase. Following hyaluronidase injection, the lymphedematous region of our model resembled a normal hind limb. Our findings indicated that hyaluronidase promoted lymphangiogenesis on the lymphedematous limb. Based on hyaluronidase treatment in the lymphedematous region, this could potentially be a new therapeutic approach for acquired lymphedema mediated through the modification of the size of HA fragments. Impact statement In this manuscript, the essence of the work described in this manuscript involves the development of (1) a mouse limb model showing acquired lymphedema and (2) a potent therapeutic treatment using hyaluronidase to remedy acquired lymphedema in our model. In order to develop a reproducible acquired lymphedema animal model that reflects the most common symptoms experienced by lymphedema patients, we devised a mouse hind limb model by removing lymph nodes and lymphatics. Our model showed the distinguishable swelling and the reliable symptoms compared to previously reported models. In the lymphedematous regions of our model, we confirmed that hyaluronic acid (HA) accumulated to higher levels than in a normal mouse. This lymphedema volume was rapidly reduced by treating the lymphedematous leg with hyaluronidase, which also degraded high molecular weight HA to low molecular weight HA. Immunohistochemical analysis, quantitative real-time PCR analysis and lymphangioscintigraphy showed that hyaluronidase enhanced lymphangiogenesis in the lymphedematous limb.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Kangsan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Sungrae</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jae-Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Byong Chul</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>2 Colorectal Cancer Branch, Division of Translational and Clinical Research I, Research Institute, National Cancer Center, Goyang 410-769, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Won-Ki</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>2 Colorectal Cancer Branch, Division of Translational and Clinical Research I, Research Institute, National Cancer Center, Goyang 410-769, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok-Ki</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>3 Molecular Imaging & Therapy Branch, National Cancer Center, Goyang 410-769, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Kyewon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>4 Department of Food Science and Biotechnology, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Hee</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>5 Department of Oriental Medical Science, Graduate School of East-West Medicine, Kyunghee University, Secheondong, Yongin 446-701, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Jin-Mo</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>6 Natural Products Research Department, Gyeonggi Institute of Science & Technology, Suwon 443-270, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeom</LastName><ForeName>Chang-Hwan</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>7 U-Cell Clinic, Seoul 137-071, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyunghoon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>8 Department of Anatomy, School of Medicine, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sukchan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Exp Biol Med (Maywood)</MedlineTA><NlmUniqueID>100973463</NlmUniqueID><ISSNLinking>1535-3699</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.2.1.35</RegistryNumber><NameOfSubstance UI="D006821">Hyaluronoglucosaminidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006614" MajorTopicYN="N">Hindlimb</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006821" MajorTopicYN="N">Hyaluronoglucosaminidase</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acquired lymphedema</Keyword><Keyword MajorTopicYN="N">hyaluronic acid</Keyword><Keyword MajorTopicYN="N">hyaluronidase and lymphangiogenesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28092183</ArticleId><ArticleId IdType="doi">10.1177/1535370216688570</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000415 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000415 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28092183
|texte= Therapeutic effects of hyaluronidase on acquired lymphedema using a newly developed mouse limb model.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28092183" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |